The adjustment in price target by Oppenheimer reflects a slight modification in their valuation assessment of ResMed, likely due to updated financial analysis or market conditions. However, maintaining the Outperform rating indicates a continued positive outlook on the company's performance. This could suggest a neutral to slightly positive short-term impact on ResMed's stock, as the market absorbs the minor adjustment in price target while considering the sustained positive rating.